NCT02584829View on ClinicalTrials.gov

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 6, 2015

Primary Completion Date

December 18, 2018

Study Completion Date

December 18, 2018

Conditions
Merkel Cell Polyomavirus InfectionStage IV Merkel Cell Carcinoma AJCC v7
Interventions
DRUG

Avelumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

BIOLOGICAL

Recombinant Interferon Beta

Given via intra-tumor injection

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT02584829 - Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma | Biotech Hunter | Biotech Hunter